A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer

Trial Profile

A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Orteronel (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Millennium; Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Mar 2016 Number of treatment arms changed from 3 to 8 with different doses of Orteronel and Prednisone.
    • 31 Mar 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top